Cardiovascular Health

The Pharmacy Times® Cardiovascular Health resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?
[[thumbnail_alt_text]]
The Clinical Performance and Quality Measures included 6 performance measures, 6 process quality measures, and a new category of 10 structural quality measures for adults with high blood pressure.
[[thumbnail_alt_text]]
Certain subgroups may see a greater reduction in heart failure hospitalizations and cardiovascular death with the combination of sacubitril and valsartan.
[[thumbnail_alt_text]]
Top news of the day from across the health care landscape.
 
[[thumbnail_alt_text]]
An analysis presented at the American Heart Association Annual Scientific Sessions showed that evolocumab (Repatha, Amgen) lowered the risk of cardiovascular events in patients who have recently had a heart attack.
[[thumbnail_alt_text]]
cvMOBIUS will examine lipid management and the effectiveness of evolocumab (Repatha, Amgen) on cardiovascular outcomes.
[[thumbnail_alt_text]]
Implementing more aggressive treatment plans from the American Heart Association’s 2017 guide were seen as more cost-effective over 10 years.
[[thumbnail_alt_text]]
The prevalence of the issue in the United States ranges from 2.7 million to 6.1 million, and this number is expected to increase to 12.1 million by 2030.
[[thumbnail_alt_text]]
Study results have shown that a regimen of once-daily edoxaban (Lixiana, Daiichi Sankyo) combined with a P2Y12 inhibitor is noninferior to the current recommended treatment for patients with atrial fibrillation following successful percutaneous coronary intervention, and may result in less bleeding.
[[thumbnail_alt_text]]
The PHARM-CHF trial investigated whether regularly seeing a pharmacist improves adherence to heart failure medications.
[[thumbnail_alt_text]]
Transthyretin amyloid cardiomyopathy is a rare and fatal disease for which there are no previously approved treatments.
[[thumbnail_alt_text]]
Top news of the day from across the health care industry.
[[thumbnail_alt_text]]
As a result of the agreement, Teva is licensed to launch a generic version of liraglutide (Victoza, Novo Nordisk) as of December 22, 2023.